Different dosing, administration of corticosteroids for severe COPD shows comparable outcomes

June 15, 2010

In contrast to clinical guidelines, new research finds that the vast major­ity of patients hospitalized for severe symptoms of chronic obstructive pulmonary disease (COPD) were initially treated with higher doses of corticoste­roids administered intravenously, with analysis indicating that these patients had outcomes comparable to patients who received the recommended and lower-cost, less-invasive treatment of low doses of steroids administered orally, according to a study in the June 16 issue of JAMA.

COPD is the fourth leading cause of death in the United States, affects more than 6 percent of adults in the U.S., and accounts for $32 billion in direct health care costs. "In 2006, there were approximately 600,000 for acute exacerbation COPD, making this 1 of the 10 leading causes of hospital­ization nationwide," the authors write. "Systemic corticosteroids are beneficial for patients hospitalized with acute exacerbation of COPD; however, their optimal dose and route of administration are uncertain."

Peter K. Lindenauer, M.D., M.Sc., of Baystate Medi­cal Center, Springfield, Mass., and colleagues investigated the use of cortico­ among patients hospitalized for acute exacerbation of COPD at 414 U.S. hospitals in 2006 and 2007. The researchers com­pared the outcomes of those initially treated with low doses of steroids ad­ministered orally to those initially administered steroids at higher doses intravenously during the first 2 hospital days. Among the outcomes the researchers analyzed included a composite measure of treatment failure, defined as the initiation of after the second hospital day, inpatient mor­tality, or readmission for acute exacerbation of COPD within 30 days of discharge.

Of 79,985 patients, 73,765 patients (92 percent) were initially treated with higher doses of steroids administered intravenously, while 6,220 (8 percent) began low doses of steroids given orally. A total of 1.4 percent of patients initially treated with intravenous steroids died during the hospitalization and 10.9 percent experienced the com­posite treatment failure outcome, whereas 1.0 percent of orally treated patients died during the hospitalization and 10.3 percent experienced the compos­ite outcome. A total of 1,356 patients (22 percent) initially treated with low-dose oral steroids were later switched to in­travenous therapy.

The researchers found that in analysis that adjusted for various factors including patient, hospital, and physician characteris­tics, the risk of treatment failure among patients given low doses of steroids orally was not sig­nificantly different from those treated with high-dose steroids intravenously. Also, pa­tients treated with low doses of ste­roids administered orally had shorter lengths of hospital stay and lower costs.

"In this large observational study, we found that, in sharp contrast to the rec­ommendations contained in leading clinical guidelines, the vast major­ity of patients hospitalized for acute exacerbation of COPD were initially treated with high doses of corticoste­roids administered intravenously. This practice does not appear to be associ­ated with any measurable clinical ben­efit and at the same time exposes patients to the risks and inconvenience of an intravenous line, potentially unnec­essarily high doses of steroids, greater hospital costs, and longer lengths of stay," the authors write.

"In light of the greater risks and higher costs as­sociated with high-dose intravenous treatment, opportunities may exist to improve care by promoting greater use of low-dose steroids given orally. Given the large numbers of patients hospital­ized with COPD each year in the United States, a clinical trial comparing these 2 approaches to management would be valuable."

More information: JAMA. 2010;303[23]:2359-2367.

Related Stories

Recommended for you

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.